MNKD Earnings

MNKD reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 96.78M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.01 by 0%. The stock experienced a -7.43% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following MNKD's earnings announcement on 2026-02-26, the stock price moved by -7.43% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, MNKD's stock price tends to shift by an average of 10.36% in the 10 days leading up to earnings and 1.31% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate MNKD's annual revenue to reach 107.80M, while the EPS is projected at -0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MNKD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MNKD's stock price typically moves by 10.36% in the 10 days before its earnings and 1.31% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.01 and revenue of 107.80M.

The earnings call summary highlights strong financial performance, with significant revenue growth driven by Afrezza and FUROSCIX. Product development is advancing, with promising pipeline updates and strategic initiatives. Market strategy and shareholder return plans are not explicitly detailed but implied through growth projections. The Q&A session reveals optimism for future revenue growth, particularly with the pediatric segment and FUROSCIX auto-injector launch. Despite some management vagueness, the overall sentiment is positive, with potential catalysts for stock price appreciation. Considering the small-cap nature, a positive stock price movement (2% to 8%) is expected.